(C6)-CP 47,497.

(C6)-CP 47,497 belongs to the cyclohexylphenol series, cannabinoids described as non-classical: the pyran ring of THC is absent, and all that remains is a phenol bearing a 3-hydroxycyclohexyl group and a branched alkyl chain. It is this chain that governs affinity for the receptors, and the C6 homologue bears one of six carbons, below the optimum of the series, maximal affinity being reached with seven or eight carbons according to the structure-activity work of Melvin and his collaborators. The lead compound CP 47,497 is a cannabimimetic agent whose potency is 3 to 28 times that of Δ9-THC according to Weissman and his collaborators (1982). For the C6 homologue itself, the only measurement found is an affinity for the CB1 receptor of about 12 µM (pKi of 4.921, Lee et al., 2020), the weakest of the four members of the series measured by those authors; no measure of efficacy and no in vivo study have been found, and human data are entirely lacking: its functional activity is inferred from its place in the series, it has not been measured.

Source

A wholly synthetic molecule, absent from hemp and from every living organism. It comes from industrial medicinal chemistry on the non-classical cannabinoids, where several side-chain lengths were prepared around CP 47,497 in order to understand the role of that chain in receptor recognition. On the market, it appeared in 2009 in 'Spice'-type products (EMCDDA, 2009).

No known biosynthetic pathway: the molecule does not exist in living things and has never been isolated from hemp. It results from total chemical synthesis in the cyclohexylphenol family, the length of the branched alkyl chain being the only variable distinguishing the homologues from one another.

European Union

No control measure at Union level has been found for this molecule, and it appears in no schedule of the 1971 United Nations Convention on Psychotropic Substances (INCB Green List, 36th edition, 2025). In early 2009, the EMCDDA and Europol judged that CP 47,497 and its homologues did not meet the criteria for a joint report, while maintaining monitoring (EMCDDA, 2009); control is a matter for the Member States. Besides France (24 February 2009), Austria banned its sale and import by a decree under its pharmaceutical law on 3 March 2009, Estonia placed it under control on 24 July 2009 and Sweden did so by a government decision of 30 July 2009 that entered into force on 15 September 2009.

France

A narcotic designated by name. CP 47,497-C6 appears in full in annex IV of the decree of 22 February 1990, under the heading for cyclohexylphenols, in the wording "CP 47,497-C6 or (5-(1,1-dimethylhexyl)-2-[(1R, 3S)-3-hydroxycyclohexyl]-phenol". It is therefore not a matter of attachment through the generic clause covering tetrahydrocannabinols, their esters and their ethers (entered in annex III of the consolidated list since the decision of 6 February 2026): the substance is cited by its name. The classification dates back to 24 February 2009, when six synthetic cannabinoids were added to that annex on a proposal from the national commission on narcotics and psychotropic substances; the heading "derivatives of 2-(3-hydroxycyclohexyl) phenol" moreover covers the whole family generically. Possession, transfer and use fall under the narcotics regime, and no lawful CBD product may contain it.

Sources: EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA. Our method.

Family

Synthetic CB receptor agonist › New psychoactive substance

Class

cyclohexylphenol (non-classical cannabinoid, C6 homologue of CP 47,497)

Verification

Classification, sources and binding values checked on 20 October 2026; text read against its sources and Wikipedia.

Wikipedia (English)

(C6)-CP 47,497 (new tab)

Article paired by the molecule's structure (InChIKey), revision read on 19 October 2026. Read as a second opinion, never cited as a source.

1. 1PubChem, CID 12788252, 2-[(1R,3S)-3-hydroxycyclohexyl]-5-(2-methylheptan-2-yl)phenol (new tab)
2. 2ANSM, consolidated list of substances classified as narcotics, updated 16 February 2026 (Annex IV, cyclohexylphenols heading: entry CP 47,497-C6; Annex III: tetrahydrocannabinols clause) (new tab)
3. 3EMCDDA (2009), Understanding the 'Spice' phenomenon, Thematic paper (identification of the C6 homologue, national control measures of 2009 including the French scheduling of 24 February 2009) (new tab)
4. 4Weissman A, Milne GM, Melvin LS Jr (1982), Cannabimimetic activity from CP-47,497, a derivative of 3-phenylcyclohexanol, J Pharmacol Exp Ther 223(2):516-523 (new tab)PMID 6290642
5. 5Melvin LS, Milne GM, Johnson MR, Subramaniam B, Wilken GH, Howlett AC (1993), Structure-activity relationships for cannabinoid receptor-binding and analgesic activity: studies of bicyclic cannabinoid analogs, Molecular Pharmacology 44(5):1008-1015 (new tab)PMID 8246904
6. 6Lee W et al. (2020), QSAR model for predicting the cannabinoid receptor 1 binding affinity and dependence potential of synthetic cannabinoids, Molecules 25(24):6057 (pKi 4.921 for CP 47,497-C6) (new tab)PMID 33371501
7. 7Jin MJ, Lee J, In MK, Yoo HH (2013), Characterization of in vitro metabolites of CP 47,497 in human liver microsomes by LC-MS/MS, Journal of Forensic Sciences 58(1):195-199 (data for the parent CP 47,497, not for the C6 homologue) (new tab)PMID 22931239
8. 8EMCDDA (2021), Synthetic cannabinoids in Europe: a review, Technical report (full CB1 agonism versus the partial agonism of THC, class toxicity, no antidote) (new tab)
9. 9INCB, Green List of psychotropic substances, 36th edition, 2025 (1971 Convention: no cyclohexylphenol) (new tab)

SMILES

CCCCCC(C)(C)C1=CC(=C(C=C1)[C@@H]2CCC[C@@H](C2)O)O

Machine-readable entry (JSON)

LLM ingestion format: a structured superset of the entry (identifiers, binding, versioned legal status). Full corpus.